

Substitute for form 1449A/PTO

**INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/815,597
Filing Date	March 23, 2001
First Named Inventor	Wolin
Group Art Unit	1632
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	PP01658.002 (035784/209107)

Sheet 1 of 1

**U. S. PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Office <sup>3</sup>	Number <sup>4</sup>	Kind Code (if known) <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
MBS	47	ATKINS, M.B., "Interleukin-2: Clinical Applications," <i>Seminars in Oncology</i> , 2002, pp. 12-17, Vol. 29(3).	
↓	48	FEHNIGER, T.A., <i>et al.</i> , "Potential Mechanisms of Human Natural Killer Cell Expansion <i>In Vivo</i> During Low-Dose IL-2 Therapy," <i>The Journal of Clinical Investigation</i> , July 2000, pp. 117-124, Vol. 106(1).	
↓	49	MEROPOL, N.J., <i>et al.</i> , "Evaluation of Natural Killer Cell Expansion and Activation <i>In Vivo</i> with Daily Subcutaneous Low-Dose Interleukin-2 Plus Periodic Intermediate-Dose Pulsing," <i>Cancer Immunology and Immunotherapy</i> , 1998, pp. 318-326, Vol. 46.	
↓	50	THUMMALA, A.R., <i>et al.</i> , "A Phase I/II Study of Rituxan and Interleukin 2 (IL-2) in Patients with Low Grade or Mantle Cell Non-Hodgkins Lymphoma (NHL)-Preliminary Results," Database Biosis Online Accession No. PREV200200152443, page 250b, Abstract 4732; appearing in <i>Blood</i> , November 16, 2001, page 250b, Vol. 98, No. 11, Part 2.	

Examiner Signature		Date Considered	4/27/02
--------------------	---	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
RTA01/2185005v1

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup> Applicant is to place an "X" here if English language Translation is attached.